Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 13/20 | 0.56 |
| ▸ | PDE4B | Q07343 | 11/20 | 0.56 |
| ▸ | PDE4D | Q08499 | 10/20 | 0.56 |
| ▸ | PDE4C | Q08493 | 9/20 | 0.56 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5319215 | 0.83 | ACHE (0.59) | — | |
| SCHEMBL7363850 | 0.81 | PDE4A (0.53) | PDE4APDE4BPDE4DPDE4CPOLB | |
| SCHEMBL27537534 | 0.81 | PDE4A (0.56) | PDE4APDE4BPDE4DPDE4CMAPK14 | |
| SCHEMBL3181116 | 0.81 | PDE4A (0.65) | PDE4APDE4BPDE4DPDE4C | |
| SCHEMBL7175088 | 0.80 | PDE4A (0.65) | PDE4APDE4BPDE4DPDE4C | |
| SCHEMBL7180229 | 0.79 | PDE4A (0.60) | PDE4APDE4BPDE4DPDE4C | |
| SCHEMBL5610531 | 0.79 | PDE4A (0.59) | PDE4APDE4BPDE4DPDE4C | |
| SCHEMBL7331340 | 0.79 | PDE4A (0.58) | PDE4APDE4BPDE4DPDE4C | |
| SCHEMBL20325922 | 0.79 | PTGS2 (0.50) | — | |
| SCHEMBL13799356 | 0.79 | PDE4A (0.61) | PDE4APDE4BPDE4DPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1567498-B1 | MANDELIC ACID DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-01-23 | — | — | EP | disclosed |
| US-7129238-B2 | Mandelic acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 2006-10-31 | — | — | US | disclosed |
| EP-1567498-A2 | MANDELIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-08-31 | — | — | EP | disclosed |
| US-20040122057-A1 | Novel mandelic acid derivatives | HOFFMANN-LA ROCHE INC. | 2004-06-24 | — | — | US | disclosed |
| WO-2004048335-A2 | MANDELIC ACID DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2004-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122057-A1 | Novel mandelic acid derivatives | F7, F11, F9 | PDE4A 1548/4885PDE4B 1664/4885PDE4D 1815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.